Clinical Trials Logo

Clinical Trial Summary

Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.


Clinical Trial Description

Cardiac amyloidosis is a cause of restrictive cardiomyopathy with preserved ejection fraction associated with amyloid fibrils deposits in the myocardium. Two types of amyloid commonly infiltrate the heart: immunoglobulin light-chain amyloid (AL), and transthyretin-related amyloid amyloidosis (ATTR). Cardiac imaging is currently used for the diagnosis of ATTR, including planar scintigraphy with bone seeking radiopharmaceuticals, cardiac magnetic resonance and echocardiography with global longitudinal strain assessment.Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04849754
Study type Interventional
Source GCS Ramsay Santé pour l'Enseignement et la Recherche
Contact Frederic MOUQUET
Phone 0642377375
Email fmouquet@ovh.fr
Status Recruiting
Phase N/A
Start date February 25, 2021
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04459169 - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting NCT06034405 - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT04915235 - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting NCT02966522 - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis Phase 2
Terminated NCT03333551 - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy Phase 4
Recruiting NCT04105634 - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT Early Phase 1
Recruiting NCT05139797 - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting NCT05593679 - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting NCT04146415 - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera N/A
Recruiting NCT03626584 - PET/MR Imaging In Patients With Cardiac Amyloidosis
Recruiting NCT04856267 - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Completed NCT03119558 - PET/MRI Evaluation of Cardiac Amyloid Early Phase 1
Recruiting NCT02798705 - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting NCT04387344 - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting NCT06129656 - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated NCT01683825 - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Phase 4
Withdrawn NCT04363294 - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot N/A
Not yet recruiting NCT04661800 - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis N/A
Terminated NCT03232632 - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. Early Phase 1